Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO
Eris Lifesciences looks to leverage its experience in integrated diabetes portfolio to take a lead among the first wave of generic semaglutide anti-diabetic and weight-loss drugs to hit the market early next year, a top official said.
The company is looking at a 'good' share of the market, Krishnakumar Vaidyanathan, executive director and chief operating officer of Eris Lifesciences, told ET in an interaction.
Semaglutide is the active ingredient in Novo Nordisk's blockbuster drugs Wegovy and Ozempic. Its patent in India will expire in March 2026. 'We are gearing up to be among the first to enter the market post loss of exclusivity,' Vaidyanathan said. 'We expect the overall market for GLP-1 at the end of the first 12 months (after the loss of exclusivity) to be at least 10 million units… And we expect to get a good share of the market.' Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist.
Eris Lifesciences' existing diabetes portfolio includes orals, insulin and GLP-1 in the form of liraglutide. Its network of field representatives, patient connect and service platform in this space gives the firm an advantage over others, Vaidyanathan said. 'We do this day in and day out because of insulin. That gives us the confidence that we'll be able to step this up for GLP-1 as well.'Globally, the GLP-1 market is dominated by Eli Lilly and Novo Nordisk, which are also the two biggest insulin companies in the world. 'Being successful and big in the insulin market provides a huge tailwind when it comes to selling GLPs,' Vaidyanathan said. 'We have combined service with technology and product to create a winning combination in insulin and GLP therapy entry is not any different, which also requires a lot of patient education over and above the service on using the pens,' he said. 'We have an integrated diabetes portfolio because we currently sell GLP-1 in the form of liraglutide.'
Dr Reddy's Labs, Sun Pharmaceutical Industries, Cipla, Mankind Pharma, Torrent Pharmaceuticals, and Zydus Lifesciences are also among Indian drugmakers readying to launch generic semaglutide next year. Eris Lifesciences launched liraglutide, a once-a-week GLP-1 product, last September. 'We have taken very good market shares in all the other LOE (loss of exclusivity) opportunities that we have seen in diabetes,' Vaidyanathan said. 'We have taken market ranks of 1 to 5 in each one without exception – vildagliptin, sitagliptin, linagliptin, dapagliflozin and empagliflozin. That gives us the confidence that we should be getting a fair share of the market.' Vishal Manchanda, pharma analyst at brokerage Systematix Group, said its full portfolio of anti-diabetes drugs to offer to diabetologist, spanning all oral and injectable options, should give Eris Lifesciences 'a strong positioning in a market where the large pharma majors like Sun, Lupin, Dr Reddy's, Cipla, Mankind and Zydus come in with their dominant brand presence.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Deccan Herald
9 minutes ago
- Deccan Herald
Single mutation in gene likely linked to sudden heart attacks, say Bengaluru scientists
Dr Dhandapany Perundurai and his team at the institute screened roughly 20,000 to 25,000 genes in Indian patients with primary cardiomyopathy.
The Hindu
9 minutes ago
- The Hindu
DAC approves defence procurement worth ₹67,000 crore to strengthen border security
The Defence Acquisition Council (DAC), chaired by Defence Minister Rajnath Singh, sanctioned multiple procurement proposals worth nearly ₹67,000 crore to strengthen the nation's military preparedness. According to the Ministry of Defence (MoD), for the Indian Army, Acceptance of Necessity (AoN) was accorded for the procurement of Thermal Imager-based Driver Night Sight for BMP. This would enhance night driving capability of BMP and provide higher mobility and operational advantage to the mechanised infantry. For the Indian Navy, AoN was accorded for the procurement of Compact Autonomous Surface Craft, BrahMos Fire Control System and launchers, and upgradation of BARAK-1 point defence missile system. The procurement of Compact Autonomous Surface Craft will provide the capability to the Navy for detection, classification and neutralisation of threats in anti-submarine warfare missions. For the Indian Air Force, AoN for procurement of mountain radars and upgradation of Saksham/Spyder weapon system was accorded. Mountain radars will enhance the air surveillance capability along and across the borders in the mountainous regions. The upgradation of Saksham/Spyder system for integration with Integrated Air Command and Control System will enhance the air defence capability, said the MoD in a statement. AoN was also accorded for the procurement of Medium Altitude Long Endurance (MALE) Remotely Piloted Aircraft (RPAs) for the three services. The proposed MALE RPAs can carry multiple payloads and weapons and operate at longer ranges for long endurance missions. They will significantly enhance round-the-clock surveillance and combat capability of the armed forces. In addition, the DAC has also accorded AoN for sustenance of C-17 and C-130J fleets and comprehensive annual maintenance contract of S-400 Long Range Air Defence Missile System.
Time of India
20 minutes ago
- Time of India
Trump escalates threat level, says more tariff in 24 hours
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel New Delhi: US President Donald Trump Tuesday threatened to 'very substantially' increase the 25% tariff on imports from India over continued purchases of Russian oil, maintaining his aggressive posture. This comes a day after New Delhi's strong response to comments by him in a similar vein over the past week or so.'India has not been a good trading partner because they do a lot of business with us, but we don't do business with them. So we settled on 25%, but I think I'm going to raise that rate quite substantially in the next 24 hours,' Trump said in an interview to CNBC that was aired on Tuesday evening in India. The US President reiterated his claim that India has the highest tariffs.'They're buying Russian oil and fuelling the war machine. If they are going to do that, I'm not going to be happy,' he said, adding that the main sticking point remained that India's tariffs were too high. 'With India, what people don't like to say is, they have the highest tariffs of anybody.'On Monday, India reacted strongly after Trump threatened substantial tariffs for purchasing Russian oil and 'selling it in the open market for big profits.'This is helping to fund Russia's war against Ukraine, according to had accused the US and the European Union of unfairly 'targeting' India when they themselves were importing essential material from Russia. 'The targeting of India is unjustified and unreasonable,' the ministry of external affairs had said.'Like any major economy, India will take all necessary measures to safeguard its national interests and economic security.' India also pointed out that the US had initially backed India's purchases from Russia 'for strengthening global energy markets stability.'Trump had last week announced a 25% duty on all Indian goods, in addition to a penalty for buying a 'vast majority' of Russian military equipment and crude oil. The US President has targeted India and Russia for their close ties and said the two can take their 'dead economies down together.'India had responded by reiterating that it will take all necessary steps to safeguard its national interest, besides pointing out that its economy — the fastest-growing major one — was a bright spot amid global had earlier threatened an additional 10% tariff on BRICS members, which he said were aligning themselves against the US. His threats come amid the two sides negotiating a bilateral trade agreement (BTA), the first part of which is planned to be concluded by trade negotiators are scheduled to visit India for the sixth round of talks on August 25-30. The US was India's largest export destination in FY25 with shipments valued at $87 billion, accounting for about a fifth of the $437 billion total.
